Rhodiola

A randomized crossover clinical trial (N=13) showed a statistically significant 21% decrease in the EXP-3174/losartan metabolic ratio after 14 days of Rhodiola rosea pretreatment, confirming CYP2C9 inhibition in vivo. Since S-warfarin is primarily metabolized by CYP2C9, inhibition could increase S-warfarin plasma concentrations and anticoagulant effect. In vitro studies confirm noncompetitive CYP2C9 inhibition. Preclinical data in rats and rabbits shows increased losartan AUC of up to 2-fold.

Monitor INR more frequently when Rhodiola is started or stopped in patients on warfarin. Advise patients to report unusual bruising or bleeding. While the CYP2C9 effect is modest in healthy volunteers, pharmacogenomic variation (CYP2C9 poor metabolizers) may experience more pronounced interaction. Avoid high-dose Rhodiola in anticoagulated patients.

Phenytoin is a narrow-therapeutic-index drug primarily metabolized by CYP2C9 and CYP2C19. Rhodiola rosea inhibits CYP2C9 (21% reduction in activity confirmed in vivo), which can reduce phenytoin clearance and raise plasma concentrations. Elevated phenytoin leads to dose-related toxicity including nystagmus, ataxia, and encephalopathy at modest increases above the therapeutic range.

Avoid high-dose Rhodiola supplementation in patients on phenytoin. If co-administration occurs, monitor phenytoin serum levels periodically and assess for signs of toxicity. Adjust phenytoin dosing if levels are consistently elevated.

Rhodiola rosea inhibits MAO-A and MAO-B enzymes, increasing synaptic monoamine levels including serotonin, dopamine, and norepinephrine. Combined with SSRI/SNRI-mediated serotonin reuptake inhibition, this produces additive serotonergic stimulation and theoretical serotonin syndrome risk. The MAO inhibitory activity is attributed to rosavin-related compounds.

Avoid combining high-dose Rhodiola with SSRIs or SNRIs without clinician supervision. If used alongside antidepressants, use the lowest effective dose. Monitor for signs of serotonin syndrome including agitation, diaphoresis, tachycardia, tremor, and diarrhea. Advise patients not to self-medicate for depression without informing their prescriber.

Rhodiola rosea has documented immunostimulatory properties including enhancement of T-cell and natural killer cell activity. Salidroside and rosavin compounds activate innate immunity. This immunostimulation may antagonize the effect of immunosuppressant therapy in transplant or autoimmune disease patients.

Avoid in transplant patients and those on immunosuppressants for autoimmune conditions. If a patient is considering Rhodiola for fatigue while on immunosuppressants, consult the managing specialist. Monitor immunosuppressant levels and clinical response.

Rhodiola has mild stimulant-like adaptogenic properties, increasing dopamine and norepinephrine availability through MAO inhibition. Combined with prescribed CNS stimulants, this may produce additive stimulatory effects including increased anxiety, agitation, restlessness, insomnia, elevated heart rate, and blood pressure.

Advise patients on methylphenidate or amphetamines that Rhodiola may amplify stimulant effects. Start Rhodiola at low doses and monitor for anxiety, insomnia, and cardiovascular effects. Consider timing to minimize interference with sleep.

Rhodiola rosea extracts stimulate the distribution of serotonin, dopamine, and noradrenaline via multiple mechanisms including weak MAO-A and MAO-B inhibition (confirmed by van Diermen et al. 2009), as well as partial serotonin receptor modulation. A published case report documented suspected serotonin syndrome in a 68-year-old woman who developed vegetative syndrome, restlessness, and trembling 15 days after beginning Rhodiola (400 mg/day) combined with paroxetine (20 mg/day); symptoms resolved within 2 days of herb discontinuation. Pharmacokinetic contribution is also possible via Rhodiola inhibition of CYP3A4, CYP2D6, and P-gp, which are key enzymes metabolising most SSRIs, potentially increasing SSRI plasma levels.

Avoid concurrent use of Rhodiola rosea with SSRIs without specialist supervision due to risk of serotonin syndrome. If co-administration is clinically necessary, begin at the lowest effective Rhodiola dose, monitor closely for early serotonin syndrome symptoms: agitation, restlessness, hyperhidrosis, tremor, tachycardia, hyperreflexia. The interaction carries a high-risk classification due to the serotonin syndrome case report. Discontinue Rhodiola immediately if serotonergic symptoms develop.

Rhodiola rosea contains constituents (including rosaridin and possibly rosavin) with demonstrated MAO-A and MAO-B inhibitory activity. Combining Rhodiola with pharmaceutical MAO inhibitors creates pharmacodynamic synergy for MAO inhibition, dramatically elevating monoamine (serotonin, dopamine, noradrenaline) levels. This combination significantly increases the risk of hypertensive crisis (from tyramine food interactions), serotonin syndrome, and hyperpyrexia - the same dangerous interaction profile as dual MAO inhibitor co-prescribing.

Contraindicated combination. Do not prescribe or recommend Rhodiola rosea to patients taking any MAO inhibitor. Advise a washout period of at least 2 weeks after stopping an MAOI before starting Rhodiola (and vice versa for irreversible MAOIs). Counsel patients on tyramine-containing foods if Rhodiola is used close to MAOI therapy.

Rhodiola rosea extracts demonstrate potent CYP3A4 inhibition in vitro, with IC50 values of 1.7-3.1 microg/mL across six R. rosea clones studied by Hellum et al. (2010). Multiple commercial R. rosea products showed IC50 values ranging from 7.2 to 186 microg/mL for CYP3A4. Preclinical pharmacokinetic studies in rabbits showed that R. rosea extract at 50 mg/kg increased losartan AUC and half-life approximately 2-fold (effects on CYP2C9/CYP3A4 and OATP). Rhodiola also inhibits P-glycoprotein in vitro. These combined CYP3A4 and P-gp inhibitory effects may significantly raise plasma concentrations of narrow therapeutic index substrates like tacrolimus, sirolimus, and midazolam.

Monitor plasma drug concentrations of CYP3A4 substrates with narrow therapeutic windows (tacrolimus, cyclosporine, sirolimus) in transplant patients using Rhodiola. For midazolam and similar sedative CYP3A4 substrates, anticipate enhanced and prolonged sedation. Reduce substrate drug dose proactively or advise avoidance of the combination in high-risk situations.

Rhodiola rosea has adaptogenic effects that modulate the HPA axis and stress hormone response including cortisol, which influences glucose metabolism. Preclinical studies indicate Rhodiola may reduce stress-induced glucose elevation and improve insulin sensitivity. The Merck Manual documents that Rhodiola could cause hypoglycemia, particularly in people taking antihyperglycemic medications. Additive blood glucose lowering effects could predispose to hypoglycemic episodes particularly in patients on insulin or sulfonylureas.

Monitor blood glucose more frequently when patients add Rhodiola rosea to antidiabetic regimens, particularly in those on insulin or sulfonylureas (highest hypoglycemia risk). Educate patients on signs of hypoglycemia: shakiness, sweating, confusion, palpitations. Consider dose reduction of the antidiabetic if clinical hypoglycemia occurs.

Rhodiola rosea exhibits weak MAO inhibitory activity, which increases noradrenaline availability and can affect blood pressure regulation. In clinical settings, the Merck Manual states that Rhodiola could reduce blood pressure and possibly cause hypotension in people already taking antihypertensive medications. The mechanism involves adaptogenic modulation of the sympathoadrenal system, combined with potential CYP3A4 inhibition affecting bioavailability of calcium channel blockers and other antihypertensives metabolised by CYP3A4.

Monitor blood pressure regularly in patients using Rhodiola alongside antihypertensives. Advise patients to report dizziness, fainting, or unusual fatigue (signs of excessive hypotension). This combination may require antihypertensive dose reduction if persistent hypotension occurs. Be particularly cautious in elderly patients with orthostatic hypotension risk.

Rhodiola rosea extract and its active constituents (salidroside, rosavin) have demonstrated hypoglycemic effects and improved insulin sensitivity in preclinical studies. Additive blood glucose lowering may occur when combined with antidiabetic medications, particularly insulin and insulin secretagogues.

Monitor blood glucose periodically when adding Rhodiola to an antidiabetic regimen. Educate patients about symptoms of hypoglycemia. This interaction is generally low risk but warrants awareness, especially in patients with type 2 diabetes on multiple agents.

Rhodiola rosea extracts may have mild antiplatelet properties based on preclinical data. Combined with antiplatelet drugs (aspirin, clopidogrel) or anticoagulants (warfarin), there is theoretical potential for additive bleeding risk. CYP2C9 inhibition by Rhodiola may additionally increase warfarin plasma levels.

Monitor INR when combining Rhodiola with warfarin. The CYP2C9 inhibition confirmed in a clinical study (N=13) is of moderate magnitude. Exercise caution perioperatively and advise patients about bleeding risks.